An early stage fund with a China-based parent investment firm built its own science park near Shanghai to help companies expand successfully into the China market. The firm invests in 3 to 5 deals a year at seed stage. The fund has particular success in fostering joint development initiatives between U.S. and China-based companies. The firm invests in companies based in the U.S., China, or Europe.

The fund invests in early-stage therapeutics, medical devices, diagnostics, and healthcare IT. The firm is particularly interested in early-stage therapeutic companies, and their second priority would be diagnostics. The firm has expertise in the oncology field, and the firm is open to looking at orphan diseases. In addition, the firm is also open to lab equipment and drug development enabling technology.

The fund supports companies who have an international business model with desires to expand into the US, China, and/or Europe.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A leading venture capital investment firm provides capital and strategic support to early stage life science companies with revolutionary technologies, as well as growth stage healthcare companies with strong market presence. Located in both USA and China, the firm is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies in both USA and China.

The firm continues to capitalize on a historic opportunity in the rapid growth of China’s healthcare industry as well as breakthroughs in life science research worldwide. With over $440 million in capital under management and support from some of the most prestigious LPs in the world, the firm is poised to deliver superior returns to their investors and create value for their entrepreneur partners.

The investment size generally ranges from $5 million to $20 million over the life of an investment. The firm seeks to make 3-5 allocations in the next year and focuses on companies that are based in the USA and China.

The firm is currently looking for new investment opportunities in biotechnology R&D, therapeutics & diagnostics, pharmaceuticals, medical devices and healthcare IT spaces. The firm is very opportunistic in terms of subsectors and indications. The firm is interested in in-licensing products or technologies for development from companies outside of China, such as USA-based companies. The firm also seeks to invest in orphan drugs. Prior investments have included medical device companies, diagnostics companies, CRO and distributors. The firm will consider companies in all stages, depending on the opportunity.

The firm seeks to invest in both private and public companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Canada with an additional USA-based office is making investments out of its vintage 2017, fourth fund and is exclusively focused on advanced materials within four verticals including energy, electronics, health and sustainability. The firm typically makes initial investments in the $1-5M range and up to $10M over the life of the investment (more or less may be initially invested depending on the deal). The firm prefers to lead deals but will also participate in a syndicate as a co-investor. With strategic LP relationships in Asia, Europe and the Middle East, the firm is open to companies globally and looks to make 3-4 new investments per year.

The firm’s primary investment thesis is technology driven, breakthrough IP. Within healthcare, the firm is interested in medical devices and diagnostics whose underlying value is in the material as well as advanced materials with antibacterial properties and the like. The firm has a particular interest in 3D printing and genomics/proteomics R&D applications. The firm does not make investments in pharmaceuticals/therapeutics of any kind. Past investments have included a manufacturer of semiconductor radiation detectors enabling a new generation of detection and imaging equipment, a company developing environmentally-benign insecticides derived from compounds found in spider venom and a company developing functional surfaces with anti-microbial and anti-fouling properties.

The firm prefers to work with experienced management teams, but is open to working with less experienced entrepreneurs or incomplete management teams given the firm can add value through corporate strategy and operational experience to help accelerate development. The firm prefers to invest in revenue-generating companies but is open to evaluating pre-revenue companies as well. The firm seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An evergreen fund based in New York and Cambridge typically invests between $500K to $3M. The firm seeks investment opportunities globally.

The firm is interested in medical devices, diagnostics, and therapeutics from early-stage to commercial-stage. Current investments include applications for the rapid detection of pathogens, oral photo-medicine, point-of-care diagnostics, and a novel use of up converting nanocrystals.

The firm does not have a management team requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global medical device company is looking for traditional M&A opportunities in mature businesses as well as strategic equity investments in early stage companies via a corporate venture fund, primarily focused on Series A through D rounds. Initial investments usually range from $2M – $3M with some capital reserved for follow on investments and are generally flexible in terms of structure, with no special rights attached. Although these investments are strategic in nature, the fund does look for financial returns. The firm looks to deploy around $20 – $30M annually into these early stage ventures, and is open to companies on a global basis.

The firm has four main business segments in orthopedic reconstruction, advanced wound management, sports medicine and ENT. The firm is open to any technologies within these areas, from services to medical devices and is beginning to look at healthcare IT solutions that have utility in these segments. The firm will look at technologies as early as prototype phase and looks to leverage their internal expertise to evaluate their viability. The company has no restrictions in terms of regulatory pathway and will look at class I through class III products.

The firm has preference for experienced management teams but has no strict company or management requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The investment arm of a non-profit hospital system affiliated with two leading medical schools is investing from a $15M fund, and usually writes checks in the $1 million range. The firm will participate mostly in Series A and B rounds but is open to considering earlier stage, non-revenue generating companies with highly disruptive technologies. Currently, the firm is focused only on USA-based investment opportunities.

The firm is seeking digital health companies with technologies that can provide significant value to their hospital system. The firm is most interested in those that address key organization priorities, which include (1) virtualization of care (i.e. telehealth), (2) operational efficiency, (3) patient and clinician experience of care. The organization is also interested in novel applications of technologies such as AI that may not impact healthcare in the short term, but may have a disruptive potential in the future. The organization is not interested in therapeutics, medical devices, or diagnostics companies.

The firm is looking to work with companies with experienced management teams. The firm does not act as a lead investor and only seeks to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The venture capital arm of a large global corporation is actively investing worldwide, and the firm’s US office invested $100m in 20 companies in 2016. The investment size varies depending on the opportunity. The firm is actively seeking new investment opportunities in the life sciences and will look globally.

The firm invests in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The firm is also interested in therapeutics, particularly synthetic biology, nanotechnology, and gene therapy. The firm is opportunistic in terms of stage of development.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com